Nephrotoxicity of Antitumoral Agents

  • J. P. Fillastre
  • G. Raguenez-Viotte
  • B. Moulin
Part of the Archives of Toxicology book series (TOXICOLOGY, volume 12)


The new concept of cancer as a systemic disease has led to the use of adjuvant chemotherapy. Indeed, in many cancers, asymptomatic metastatic dissemination occurs in early stages of the disease and the aim of early adjuvant chemotherapy is to prevent poor subsequent evolution. The rapid development of chemotherapy has led to the common use of more than 50 drugs, many of them in association. Side-effects of these antitumoral agents are numerous. Physicians were first preoccupied with the digestive and myelodepressive effects and little attention was paid to drug-induced nephrotoxicity. Only few and recent data on the nephrotoxicity of antitumoral agents will be discussed here. The reader may consult reviews on this subject recently published (Fillastre et al. 1987; Raymond 1984; Weiss and Poster 1982).


Acute Renal Failure Hemolytic Uremic Syndrome Antitumoral Agent Antineoplastic Drug Renal Tubular Acidosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Campbell AB, Kaiman SM, Jacobs C (1983) Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Resp 67:169–174Google Scholar
  2. Cattell V (1985) Mitomycin-induced hemolytic uremic kidney. Am J Pathol 121:88–95PubMedGoogle Scholar
  3. Daley-Yates PT, Mc Brien DCH (1982) The inhibition of renal ATPase by cisplatin and some biotransformation products. Chem Biol Interact 40:325–333PubMedCrossRefGoogle Scholar
  4. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW (1980) Mechanism of cis-plastinum nephrotoxicity. II. Morphologic observations. J Pharmacol Exp Ther 213:551–556PubMedGoogle Scholar
  5. Favre R, Pignon T, Lena N, Cano JP, Carcassonne Y (1983) Maîtrise de la toxicité du methotrexate à forte dose par la surveillance pharmacocinétique. Nouv Presse Med 12:2400–2403Google Scholar
  6. Fulastre JP, Viotte G, Morin JP, Moulin B (1987) Néphrotoxicité des agents antitumoraux. In: Crosnier J, Funck-Brentano JL, Bach JF, Grünfeld JP (eds) Actualités néphrologiques de l’hôpital Necker, vol 1. Flammarion, Paris, pp 161–200Google Scholar
  7. Goldstein RS, Mayor GH (1983) The nephrotoxicity of cisplatin. Life Sci 32:685–688PubMedCrossRefGoogle Scholar
  8. Gordon JA, Gattone VH (1986) Mitochondrial alterations in cisplatin induced acute renal failure. Am J Physiol 250:F991–F998PubMedGoogle Scholar
  9. Levi J, Jacobs C, Mc Tigue M, Weiner MM (1978) Effects of cis-diamminedichloroplatinum on renal sulfhydryl groups. Kidney Int 14:728Google Scholar
  10. Nechay BR, Neldon SL (1984) Characteristics of inhibitions of human renal adenosine triphosphatases by cisplatin and chloroplatinic acid. Cancer Treat Resp 68:1135–1141Google Scholar
  11. Offerman JJG, Meijer S, Sleijfer DTH, Mulder NH, Donker AJM, Schraffordt-Koops H, Van der Hem GK (1984) Acute effects of cw-diamminedichloroplatinum (CDDP) on renal function. Cancer Chemother Pharmacol 12:36–38PubMedCrossRefGoogle Scholar
  12. Raymond JR (1984) Nephrotoxicities of antineoplastic and immunosuppressive agents. In Current problems in cancer Vol 8, Year Book Med Publ Chicago, pp 5–24Google Scholar
  13. Remuzzi G, Imberti L, Rossini M, Morelli C, Carminad C, Cattaneo GM, Bertani T (1985) Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis. J Clin Invest 75:94–101PubMedCrossRefGoogle Scholar
  14. Ryckelynck JPH, Heron JF, Juret P, Schneider P, Herlin P, De Ranieri E, Hardouin A, Peny J, Le Talaer JY (1984) Toxicité rénale du 9-hydroxy-2-methylellipticinium. Néphrologie 5:59–63PubMedGoogle Scholar
  15. Simmons CF, Humes HD (1979) Inhibitory effects of cis-diamminedichloroplatinum (cis P) on renal cortical mitochondrial respiration: a primary pathogenic event in cis-P-nephrotoxicity. Kidney Int 16:862Google Scholar
  16. Thyss A, Milano G, Kubar J, Namer M, Schneider M (1986) Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet i:256–258CrossRefGoogle Scholar
  17. Viotte G, Lahouel M, Ducastelle T, Morin JP, Fillastre JP (1988) CCNU-Adriamycin association induces earlier and more severe nephropathy in rats. Arch Toxicol 61:282–291CrossRefGoogle Scholar
  18. Weiss RB, Poster DS (1982) The renal toxicity of cancer chemotherapeutic agents. Cancer Treat Rev 9:37–52PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • J. P. Fillastre
    • 1
    • 2
  • G. Raguenez-Viotte
    • 1
  • B. Moulin
    • 1
  1. 1.Service de Néphrologie - U.E.R. RouenUnité INSERM U 295RouenFrance
  2. 2.Hôpital de Bois GuillaumeBois GuillaumeFrance

Personalised recommendations